Currently Viewing:
Evidence-Based Oncology October 2017
Formulary Considerations: The Past, Present, and Future
Molly Billstein Leber, PharmD, BCPS, FASHP
Pharmacy's Changing Role as Cancer Care Transitions From Infused to Oral Therapies
Stacey McCullough, PharmD, and Ricky Newton, CPA
Pharmacy Team Engagement in Navigating the Revenue Cycle for High-Cost Medications in Patients With Cancer
Brandon R. Shank, PharmD, MPH, BCOP; Phuoc Anh (Anne) Nguyen, PharmD, MS, BCPS; and Emily C. Pherson, PharmD, BCPS
In Conversation With a Pharmacist: Management of CAR T-Cell Treatment
Surabhi Dangi-Garimella, PhD
PBMs: Their Role, the Problems, and How Practices Can Work With Them
Ray Bailey, RPh, and Ricky Newton, CPA
Currently Reading
Positive Quality Interventions: An Innovative Platform for Oncology Practice Collaboration
Joshua Nubla, PharmD; Neal Dave, PharmD; and Michael Reff, RPh, MBA
AJMC®tv Interviews, October 2017
Produced by Laura Joszt and The Center for Biosimilars®

Positive Quality Interventions: An Innovative Platform for Oncology Practice Collaboration

Joshua Nubla, PharmD; Neal Dave, PharmD; and Michael Reff, RPh, MBA
An in-depth look into a nationwide collaborative initiative to standardize and improve oncology dispensing practices for the benefit of patient/provider education, adherence, and overall care.
The PQI pipeline developed by NCODA is dictated by the reported needs of NCODA members and includes broad topics such as medication-related adverse event management. With the addition of practices in various degrees of size and scope, the network of information developed will help create standardized resources for a growing range of healthcare systems. The sharing of best practices facilitates the evolution and improvement of oncology care across the healthcare setting.3

NCODA’s constantly growing list of PQIs has been addressing the following topics:

  • Hand-foot syndrome
  • Stomatitis
  • Chemotherapy-induced diarrhea
  • Metastatic colorectal cancer (mCRC)
  • Epidermal growth factor receptor medications
  • Polycythemia vera
  • Myelofibrosis
  • mCRC (tri uridine and tipiracil)     
  • Dose reduction practices
  • Specific drug-based follow-up call schedule
  • Olanzapine use for nausea prevention
  • Hepatocellular carcinoma
  • Cyclin-dependent kinase 4 inhibitors
Conclusion

Advancing the value of dispensing practices for oncology physicians constitutes a significant part of the NCODA mission. The need for best dispensing practices in the oncology setting is increasingly becoming apparent, and PQIs play an integral role in helping achieve this. With the PQI initiative, NCODA members across cancer centers can use their collaborative power to develop best practices that can lead to the best possible patient care.

Pharmacists, nurses, pharmacy technicians, and physicians make up the diverse group of NCODA’s membership. Each professional contributes and helps make the organization and its mission possible and successful. By creating a new type of progressive practice network focused on standardizing the oncology field, NCODA is able to prepare for the incoming wave of oral oncology medications that cover more tailored therapy regimens across a wide pool of varying patient demographics. Positive quality interventions are designed to fulfill the triple aim of improving patient satisfaction and care quality, improving the health of the overall population, and reducing the per capita cost of healthcare.1 With future data-collection methods and a pipeline of PQI creation in place, these standardized practices will help extend patient therapy and prevent loss of efficacy which will lead to better care throughout the comprehensive oncology space. 

AUTHOR INFORMATION

Joshua Nubla, PharmD, is assistant manager of stakeholder engagement, National Community Oncology Dispensing Association, Inc.
Neal Dave, PharmD, is area pharmacy manager, Texas Oncology.
Michael Reff, MBA, is executive director and founder, National Community Oncology Dispensing Association, Inc; and pharmacy manager, The Patient Rx Center, Hematology and Oncology Associates of Central New York. 

ADDRESS FOR CORRESPONDENCE

Joshua Nubla PharmD
9 Albany St, Ste 2E
Cazenovia, New York 13035 

E-MAIL

joshua.nubla@ncoda.org 
REFERENCES

1. Berwick DM, Nolan TW, Whittington J. The triple aim: care, health, and cost. Health Aff (Millwood). 2008;27(3):759-769. doi: 10.1377/ hlthaff.27.3.759.

2. Tipton J. Oral therapies: strategies to ensure adherence. Oncology Nurse Advisor website. oncologynurseadvisor.com/navigation-summit-2017/ strengthening-oral-adherence-to-oncology-medications/article/669366/. Published June 17, 2017. Accessed August 14, 2017.

3. Quality standards. NCODA website. ncoda.org/quality-standards. Published 2017. Accessed August 1, 2017. 
PDF
 
Copyright AJMC 2006-2018 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.
x
Welcome the the new and improved AJMC.com, the premier managed market network. Tell us about yourself so that we can serve you better.
Sign Up
×

Sign In

Not a member? Sign up now!